Letter to the Editor on "Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options".

@article{Ibrahim2017LetterTT,
  title={Letter to the Editor on "Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options".},
  author={Jennifer Ibrahim and Rebecca Call},
  journal={Hospital pharmacy},
  year={2017},
  volume={52 11},
  pages={
          725-726
        }
}
To the Editor: We are writing to you regarding the article referenced above by Van Rossum and Holsopple, “Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options,” because we believe that the article does not currently comply with Hospital Pharmacy’s dedication to “the promotion of best practices and medication safety.” The article contains several inaccuracies regarding the epidemiology of Gaucher disease, the available evidence regarding treatment, and the… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Clinical Pharmacogenetics Implementation Consortium guideline ( CPIC ) for CYP 2 D 6 and CYP 2 C 19 genotypes and dosing of tricyclic antidepressants :

JK Hicks, K Sangkuhl, JJ Swen
  • Blood
  • 2017

update

MJ Peterschmitt, GF Cox, J Ibrahim
  • Clin Pharmacol Ther
  • 2016

Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial

PK Mistry, E Lukina, H Ben Turkia
  • CERDELGA ( eliglustat ) [ package insert ]
  • 2015
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…